Ron Price - Accelerate Diagnostics President

AXDX Stock  USD 1.42  0.09  5.96%   

President

Mr. Ron Price is Senior Vice President and Head of Commercial Operations, Americas of the Accelerate Diagnostics Inc. Mr. Price has served as Senior Vice President and Head of Commercial Operations, Americas since April 2015. Mr. Price has over 20 years of commercial operations experience and a proven track record of leading sales and marketing teams to achieve doubledigit revenue growth and strong bottomline performance. Prior to joining the Company, Mr. Price served as Vice President, Commercial Operations for Roche Point of Care managing all commercial responsibilities across three separate product lifecycles. In addition, Mr. Price held a number of sales, marketing, and leadership roles with Ventana Medical Systems from 2001 to 2012 following five years at Bayer Healthcare Diagnostics since 2017.
Age 60
Tenure 7 years
Address 3950 South Country Club Road, Tucson, AZ, United States, 85714
Phone520 365 3100
Webhttps://acceleratediagnostics.com
Price holds a B.S. in Clinical Laboratory Sciences, Cytology from the University of Oklahoma.

Accelerate Diagnostics Management Efficiency

The company has return on total asset (ROA) of (0.7585) % which means that it has lost $0.7585 on every $100 spent on assets. This is way below average. Accelerate Diagnostics' management efficiency ratios could be used to measure how well Accelerate Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 3.25 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (1.87). At this time, Accelerate Diagnostics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.9 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 5.4 M in 2024.
Accelerate Diagnostics currently holds 39.22 M in liabilities with Debt to Equity (D/E) ratio of 2.76, implying the company greatly relies on financing operations through barrowing. Accelerate Diagnostics has a current ratio of 4.39, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Accelerate Diagnostics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Daniel GerritzenOrthopediatrics Corp
54
Patrick BeyerCONMED
58
Joseph FlanaganInteger Holdings Corp
61
Jennifer BoltInteger Holdings Corp
55
Heather CohenCONMED
51
Payman KhalesInteger Holdings Corp
54
James CunniffElectromed
58
Stephanie BoltonLivaNova PLC
42
Jim StephensInteger Holdings Corp
50
MBAMSHA CHEOrthopediatrics Corp
52
Daniel JonasCONMED
56
John KennedyCONMED
66
Keyna SkeffingtonLivaNova PLC
61
William HaydonAvanos Medical
57
Ryan MillerLivaNova PLC
N/A
David BaileyOrthopediatrics Corp
45
Terence BergeCONMED
54
Stanley PetersCONMED
45
Joel BeckerInteger Holdings Corp
53
Aviva McPherronOrthofix Medical
N/A
Michael GreinerAvanos Medical
51
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona. Accelerate Diagnosti operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 220 people. Accelerate Diagnostics (AXDX) is traded on NASDAQ Exchange in USA. It is located in 3950 South Country Club Road, Tucson, AZ, United States, 85714 and employs 134 people. Accelerate Diagnostics is listed under Life Sciences Tools & Services category by Fama And French industry classification.

Management Performance

Accelerate Diagnostics Leadership Team

Elected by the shareholders, the Accelerate Diagnostics' board of directors comprises two types of representatives: Accelerate Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Accelerate. The board's role is to monitor Accelerate Diagnostics' management team and ensure that shareholders' interests are well served. Accelerate Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Accelerate Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Lawrence Mertz, Chief Officer
Michael Bridge, Gen VP
Laura Costa, VP Support
Rita Boukamel, Senior EMEA
Jack Phillips, President CEO
Maya Gowri, Senior Operations
Ron Price, Senior Vice President Head - Commercial Operations
Cherif Bousselham, VP EMEA
Chris Thode, Senior Commercial
Steve Reichling, CFO, Chief Accounting Officer and Secretary
Gretchen Strohminger, Senior Culture
John Meduri, Chief Officer
Laura Pierson, Investor Officer
David Patience, Principal CFO

Accelerate Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Accelerate Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Accelerate Stock Analysis

When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.